Publicacións en colaboración con investigadores/as de Hospital Universitario La Fe (9)

2023

  1. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

    Journal of Clinical Oncology, Vol. 41, Núm. 28, pp. 4478-4485

  2. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

    Therapeutic Advances in Medical Oncology, Vol. 15

2022

  1. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  2. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

2021

  1. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

    BMC Cancer, Vol. 21, Núm. 1

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

  2. Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 21, Núm. 4, pp. 534-538

2017

  1. New clinical trials regulation in Spain: analysis of royal decree 1090/2015

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 291-300

2014

  1. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: A multi-center phase II study

    Anticancer Research, Vol. 34, Núm. 4, pp. 1959-1966